Stem Cells for Knee Arthritis: What the 2026 Trials Actually Show

Most stem cell clinics will show you the good study.

We are going to show you three things. The good study. The bad study. And the guideline that came out a few weeks ago telling doctors not to use stem cell injections for knee arthritis at all.

Why would a stem cell company write that post? Because you are going to find all three on your own anyway. And if you are thinking about stem cell therapy for knee osteoarthritis, you deserve to make that call with the full picture, not the sales version.

Do Stem Cell Injections Work for Knee Osteoarthritis?

Short answer: it is not settled. Some trials show better pain and function scores. Others show nothing beyond placebo. The trials use different cells, different doses, different numbers of shots, and different patients. So when someone says "the research shows stem cells work for knees," your next question should be: which research, which cells, compared to what?

Let's go through the two newest trials, one at a time.

Trial 1: Four Umbilical Cord Stem Cell Shots vs. Hyaluronic Acid

In August 2026, a team at Army Medical University in Chongqing, China, published a randomized trial in Stem Cell Research & Therapy (Chen et al., 2026). They called it triple-blind.

Who was in it

Fifty people with advanced knee osteoarthritis, Kellgren-Lawrence grade III to IV. That is the "bone is getting close to bone" end of the scale. Twenty-five got umbilical cord mesenchymal stem cells (UC-MSCs). Twenty-five got sodium hyaluronate, the lubricating "gel shot" many people have already tried.

How it was done

The stem cell group got four injections, two weeks apart. The hyaluronic acid group got five weekly injections, which is that product's usual schedule. Patients were checked at 1, 3, 6, and 12 months.

What they found

• Pain: on a 0 to 10 scale, the stem cell group went from 7.2 to 3.36 at 12 months, a drop of 3.84 points. The hyaluronic acid group dropped 2.42 points.
• Function: WOMAC scores (a standard knee pain, stiffness, and function questionnaire) fell 23.2 points in the stem cell group vs. 15.6 in the hyaluronic acid group.
• MRI: a cartilage repair score (MOCART) improved more in the stem cell group, 13.6 points vs. 7.8. Bone marrow edema cleared in 80% vs. 44%.
• Safety: no serious adverse events in either group over the year.

That is a real result in a peer-reviewed journal. It is also a long way from proof.

Trial 2: One Shot of Fat-Derived Stem Cells vs. Salt Water

Now the other side. The ADIPOA2 trial was run across several European countries and published in the Annals of the Rheumatic Diseases in 2025 (Pers et al., 2025). This one used the toughest comparison there is: saline placebo, with patients and doctors both blinded.

Who was in it

People with mild to moderate knee OA, average age 58. A total of 135 were randomized between 2016 and 2022. Ninety-nine actually received their assigned treatment and 97 were analyzed.

How it was done

Each patient got one injection. Either a low dose (2 million) or a high dose (10 million) of their own fat-derived, lab-expanded mesenchymal stromal cells, or saline.

What they found

At six months, 47.3% of the stem cell patients were "strict responders" on pain or function. In the saline group it was 54.8%. Placebo came out slightly ahead, though the difference was not statistically significant. The secondary outcomes, including cartilage thickness on MRI, showed no meaningful difference either. Serious adverse events were similar across groups, according to The Limbic's report on the trial.

The investigators did not hold back. As quoted by The Limbic: "Our findings do not support the use of ADSCs in subjects with symptomatic mild-to-moderate tibiofemoral knee OA."

They also said something every patient should read twice. Many of the positive earlier results "were obtained from open studies," and "it is entirely possible that the lack of blinding in prior trials influenced the reported improvement in symptoms."

Translation: when people know they got the expensive new treatment, they tend to feel better. That is not a knock on anyone. It is why blinded, placebo-controlled trials exist.

Why Did the Two Trials Land So Far Apart?

Nobody can say for sure from two trials. But look at how differently they were built:

The ADIPOA2 investigators listed the same suspects: how the cells are produced, how many cells and how much volume, how many injections, how far apart, which outcomes are measured, and which patients are enrolled. Any one of those could change the result. That is exactly why you can't take a study on one product and slap it on another.

What Did the American College of Rheumatology Say in 2026?

This is the part a lot of clinics will skip, so we'll put it right here.

On September 8, 2026, the ACR Board approved an update to its osteoarthritis guideline. In its published summary, it says: "In people with knee and hip OA, we strongly recommend against stem cell injections." It rates the certainty of evidence for that recommendation as moderate. The full manuscript has not been published yet. (Healio covered the update on September 14.)

That is not new. The 2019 ACR/Arthritis Foundation guideline also strongly recommended against stem cell injections for the knee and hip, citing "heterogeneity and lack of standardization in available preparations of stem cell injections, as well as techniques used." In plain words: every clinic injects something different, so it is hard to know what is being tested.

Two more things from the 2026 summary are worth knowing:

• It conditionally recommends against hyaluronic acid injections for knee OA too. So the comparison treatment in the Chen trial is not one the ACR favors.
• What it does strongly recommend for knee OA: exercise, weight loss when appropriate, self-management programs, topical and oral NSAIDs when appropriate, and ultrasound-guided steroid injections.

You may not like that. Plenty of people have done the exercise and the pills and the steroid shots and are still hurting. We get it. But the guideline is what it is, and you should know it before anyone puts a needle in your knee.

Can Stem Cells Regrow Knee Cartilage?

Nobody has shown that in a way that holds up. The Chen trial reported better MRI cartilage repair scores than hyaluronic acid in a small group. The ADIPOA2 trial found no meaningful difference in cartilage thickness compared with placebo. The most common explanation researchers give is that MSCs act mainly by signaling, calming inflammation and influencing nearby cells, rather than by turning into new cartilage. If a clinic tells you its shot will "regrow your cartilage," ask them for the controlled trial on their exact product. You probably won't get one.

So Why Would Anyone Still Consider It?

Fair question. Here is the honest version.

Some people with knee arthritis have already done the recommended basics and still have pain. Some aren't ready for, or aren't candidates for, knee replacement yet. Some have read the positive trials and want to make an informed choice about an option that isn't FDA-approved. That is an adult decision, and it belongs to you and your doctor.

What you should not do is make it based on a brochure. Make it knowing the guideline, the mixed trials, the cost, and the fact that results vary a lot from person to person.

Questions to Ask Any Stem Cell Clinic About Your Knee

• What exactly are you injecting? Umbilical cord, fat, bone marrow? Donor or your own cells?
• Has this exact product been tested in a published, controlled trial for knee OA? Not "stem cells in general." This product.
• How many injections, and how many cells? The trials above used anywhere from one shot to four.
• Who does the injection, and is it image-guided?
• What are the side effects you actually see? Read our page on stem cell therapy side effects before you go in.
• What is the FDA status? If they say "FDA-approved," walk out. See our guide to stem cell therapy and FDA approval.
• What happens if it doesn't help? A straight answer here tells you a lot about the clinic.

Where The Stem Cell Club Fits

We offer umbilical cord Wharton's Jelly MSC options, including an injection, sourced from an FDA-registered U.S. lab. FDA registration covers the lab's facility and manufacturing standards. It is not FDA approval of the product, and our offerings are not FDA-approved to diagnose, treat, cure, or prevent any disease.

Our cells are not the cells used in the Chen trial or the ADIPOA2 trial. Neither study tells you how our product, or anyone else's, will work in your knee. We won't pretend otherwise.

Here is what we will do. On a free consultation, our licensed team will look at your history and imaging, tell you what we offer and what we don't, and tell you plainly if we think you would be better off with physical therapy, weight loss support, or an orthopedic surgeon first. Sometimes that is the answer. If you want more background first, our knee research overview and our explainer on IV vs. injection are good places to start. And if you've been comparing clinics on cell counts, read why cell count alone tells you little.

For more on how fast the wider stem cell field is moving, and why "approved somewhere" doesn't mean "proven everywhere," see our breakdown of Japan's first iPS cell therapy approvals.

Frequently Asked Questions